Induction, Consolidation and Intensification Therapy for Patients Younger Than 66 Years With Previously Untreated CD33 Positive Acute Myeloid Leukemia (AML) (MYFLAI07)

University Hospital, Udine, Italy

Status and phase

Completed

Phase 3

Phase 2

Conditions

Acute Myeloid Leukemia

Treatments

Drug: FLAIMy - Fluda, Ida, Ara-C, Mylotarg

Study type

Interventional

Funder types

Other

Identifiers

NCT00909168

MYFLAI07

Details and patient eligibility

About

This is a prospective, open, non-randomized, non-controlled, phase II, clinical trial for treatment of newly diagnosed AML patients, younger than 66 years.

Trial is based on:

INDUCTION: FLAI + Gemtuzumab-Ozogamicin (FLAI-GO).
CONSOLIDATION: Intermediate dose AraC + IDA (IDAC+IDA) +/- one course of high dose AraC (HDAC)
INTENSIFICATION: Allo-BMT, ASCT
MAINTENANCE: AraC

a) Primary endpoints:
Feasibility, Efficacy (CR+PR rate) and Toxicity of FLAI + Gemtuzumab-Ozogamicin.
RFS, DFS and OS.

b) Secondary endpoints:
Evaluation of Minimal Residual Disease by WT1 (and other biologic markers) expression and monitoring.
Evaluation of prognostic clinical relevance of biological features at onset.
Feasibility and outcome of consolidation with BMT.

Enrollment

130 patients

Sex

All

Ages

18 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Age 18-65 years.
WHO PS grade 0-2 (Appendix B) or Karnofsky > 70.
AML according to the new WHO criteria, i.e., % of BM blasts ≥ 20%. NB. this % should be assessed on a BM aspiration or on a BM biopsy
All FAB subtypes except M3.
CD33 positivity (> 20%). It is mandatory to perform an immunotyping of the BM blasts in particular the determination of CD33 positivity, which will be used as a inclusion factor.
Previously untreated (except ≤ 14 days of Hydroxyurea) primary or secondary AML (including AML after MDS).
Adequate renal and liver function, i.e., creatinine < 2 mg/dl and bilirubin, ALT/AST ≤ 3 times the upper limit of normal.
Written informed consent

Exclusion criteria

Blast crisis of chronic myeloid leukemia.
AML supervening after other myeloproliferative diseases.
AML de novo or secondary previously pretreated.
Concomitant malignant disease.
Active central nervous system (CNS) leukemia.
Active uncontrolled infection [NB severe systemic infection should be excluded].
Concomitant severe cardiovascular disease, i.e., arrhythmias requiring chronic treatment, congestive heart failure or symptomatic ischemic heart disease.
Cardiac ejection fraction of 50% or less.
Severe pulmonary dysfunction (CTC grade 3-4).
Severe concomitant neurological or psychiatric disease.
History of alcohol abuse.
HIV positivity.
Pregnancy.
Man and woman not agreeing to the adequate contraceptive precautions during study period and for at last 24 months after stop of therapy.
Any psychological, familiar, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule.